<p>This is a summary of the European public assessment report (EPAR) for Pregabalin Sandoz. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Pregabalin Sandoz.</p><p>For practical information about using Pregabalin Sandoz, patients should read the package leaflet or contact their doctor or pharmacist.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p><strong>Neuropathic pain</strong></p> <p>Pregabalin Sandoz is indicated for the treatment of peripheral and central neuropathic pain in adults.</p> <p><strong>Epilepsy</strong></p> <p>Pregabalin Sandoz is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.</p> <p><strong>Generalised Anxiety Disorder</strong></p> <p>Pregabalin Sandoz is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.</p> </div>
Therapeutic Area (MeSH)
ATC Code
N02BF02
ATC Item
N/A
Pharmacotherapeutic Group
Other analgesics and antipyretics
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| pregabalin | N/A | pregabalin |
EMA Name
Pregabalin Sandoz
Medicine Name
Pregabalin Sandoz
Aliases
N/ANo risk management plan link.
